Dihydropyridine compound and application thereof to drugs
By developing new dihydropyrimidine compounds and their pharmaceutical compositions, we have solved the problems of activity and resistance in existing anti-HBV drugs, achieved effective inhibition and prevention of hepatitis B virus, and provided safer and more efficient treatment. plan.
Patent Information
- Application Number
- CN201811210586.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-10
- Filing Date
- 2018-10-17
- Publication Date
- 2019-04-26
- Estimated Expiration
- 2038-10-17
AI Technical Summary
Existing anti-hepatitis B virus (HBV) drugs such as interferon and lamivudine have problems with moderate activity, toxic side effects and drug resistance, and there is a lack of effective new drugs to replace existing treatment options.
A new type of dihydropyrimidine compound and its pharmaceutical composition have been developed, which have good pharmacokinetic properties, solubility, stability and low toxicity. They can effectively inhibit HBV infection and change the structure of the nucleocapsid by interacting with the core protein. angle to accelerate its degradation.
The novel compounds and compositions show excellent effects in preventing and treating HBV infection, have less toxicity and high antiviral activity, and can effectively replace existing drugs and reduce or prevent the replication of HBV virus.
